This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wasylyk, C. Articles by Wasylyk, B. Search for Related Content PubMed PubMed Citation Articles by Wasylyk, C. Articles by Wasylyk, B.

Inhibition of the Ras-Net (Elk-3) Pathway by a Novel Pyrazole that Affects Microtubules

¹ Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Sante et de la Recherche Medicale/Université Louis Pasteur, Illkirch Cedex, France and ² Sanofi-Aventis, Oncology Therapeutic Department, Vitry-sur-seine, France

Requests for reprints: Bohdan Wasylyk, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Parc d'Innovation, 1 Rue Laurent Fries, BP 10142, 67404 Illkirch Cedex, France. Phone: 33-3-88-65-34-11; Fax: 33-3-88-65-32-01; E-mail: boh{at}igbmc.u-strasbg.fr.

Key Words: FGF-2 • combretastatin • docetaxel • vincristine • tubulin • actin • Sap-2 • ERP • Erk-1/2

Net (Elk-3/SAP-2/Erp) is a transcription factor that is phosphorylated and activated by the Ras–extracellular signal-regulated kinase (Erk) signaling pathway and is involved in wound healing, angiogenesis, and tumor growth. In a cell-based screen for small molecule inhibitors of Ras activation of Net transcriptional activity, we identified a novel pyrazole, XRP44X. XRP44X inhibits fibroblast growth factor 2 (FGF-2)–induced Net phosphorylation by the Ras-Erk signaling upstream from Ras. It also binds to the colchicine-binding site of tubulin, depolymerizes microtubules, stimulates cell membrane blebbing, and affects the morphology of the actin skeleton. Interestingly, Combretastin-A4, which produces similar effects on the cytoskeleton, also inhibits FGF-2 Ras-Net signaling. This differs from other classes of agents that target microtubules, which have either little effect (vincristine) or no effect (docetaxel and nocodazole) on the Ras-Net pathway. XRP44X inhibits various cellular properties, including cell growth, cell cycle progression, and aortal sprouting, similar to other molecules that bind to the tubulin colchicine site. XRP44X has the potentially interesting property of connecting two important pathways involved in cell transformation and may thereby represent an interesting class of molecules that could be developed for cancer treatment. [Cancer Res 2008;68(5):1275–83]

This article has been cited by other articles:

				E. L. Schwartz Antivascular Actions of Microtubule-Binding Drugs Clin. Cancer Res., April 15, 2009; 15(8): 2594 - 2601. [Abstract] [Full Text] [PDF]